Immunovant IMVT Income Statement (2018-2026)

NASDAQ IMVT
$39.07 -0.05 (-0.13%)
As of: Sep 4, 2026 · 11:49 AM EDT
Reported Financials

Immunovant Quarterly Income Statement

Periods 31 quarters
Latest Jun 2026

Immunovant reported net income of -$153.22M for the quarter ended Jun 2026. This income statement covers 31 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
115.00M115.11M116.48M116.52M116.61M129.26M130.33M130.57M131.44M145.09M145.58M146.20M146.57M147.20M170.11M171.07M174.53M203.32M203.94M206.26M
Operating items
Research & DevelopmentR&D
21.36M29.76M31.99M28.43M37.74M42.25M51.84M50.58M47.96M48.34M66.06M75.47M97.27M94.52M93.65M101.20M114.25M98.92M142.29M142.63M
Selling, General & AdministrativeSG&A
16.29M11.52M15.24M11.95M11.88M11.78M12.42M15.40M13.84M13.21M14.82M18.81M18.47M19.78M20.17M26.02M17.51M15.44M17.27M17.69M
Other Operating ExpensesOther Opex
10.00M12.50M
Operating ExpensesOpex
37.65M41.27M47.23M40.38M49.61M64.03M64.26M78.48M61.80M61.55M80.88M94.28M115.74M114.30M113.83M127.22M131.76M114.36M159.55M160.32M
Operating IncomeOp. Inc
EBIT
-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M-153.22M
Non-operating items
Non Operating Interest Expenses
Interest & Investment IncomeInt & Inv Inc
4.07M3.57M8.93M8.38M7.18M6.07M4.59M6.89M6.34M5.60M5.33M8.06M7.09M
Other Non Operating IncomeOther Non Op Inc.
-0.08M-0.11M0.04M0.35M0.79M-1.76M0.36M0.46M0.02M1.09M-2.59M0.03M0.63M-1.26M1.07M1.19M0.25M-0.05M0.80M0.00M
Net income details
EBT
-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M-153.22M
Tax ProvisionsTaxes
-0.03M-0.01M0.35M0.26M0.39M-0.99M-0.01M0.45M-0.11M0.23M0.08M0.08M0.15M0.58M0.91M0.59M1.55M-2.84M
Profit After TaxPAT
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Income from Continuing OperationsIncome (Continuing)
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Consolidated Net IncomeConsol Net Inc.
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Income towards Parent CompanyParent Net Inc
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Net Income towards Common StockholdersNet Income
-37.70M-41.38M-47.17M-40.37M-47.93M-63.23M-59.43M-73.94M-58.66M-51.42M-75.32M-87.15M-109.12M-111.12M-106.45M-120.61M-126.50M-110.64M-147.86M-153.22M
Additional items
EPS (Basic)
-0.35-0.36-0.43-0.35-0.41-0.49-0.48-0.57-0.45-0.36-0.55-0.60-0.74-0.76-0.70-0.71-0.73-0.61-0.81-0.75
EPS (Diluted)
-0.35-0.36-0.43-0.35-0.41-0.49-0.48-0.57-0.45-0.36-0.55-0.60-0.74-0.76-0.70-0.71-0.73-0.61-0.81-0.75
Shares Outstanding
109.08M115.03M109.68M116.56M116.57M128.57M123.08M130.50M131.16M144.52M138.10M146.09M146.47M146.92M151.57M170.87M173.64M181.51M182.42M205.55M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
109.08M115.03M109.68M116.56M116.57M128.57M123.08M130.50M131.16M144.52M138.10M146.09M146.47M146.92M151.57M170.87M173.64M181.51M182.42M205.55M
EBITDA
-37.73M-41.38M-47.18M-40.02M-47.67M-62.84M-60.42M-73.95M-58.21M-51.53M-75.09M-87.07M-109.04M-110.97M-105.87M-119.70M-125.91M-109.08M-150.70M-153.22M
Interest ExpensesInt Expense
Tax Rate
0.080.03-0.88-0.55-0.621.640.01-0.780.21-0.31-0.09-0.07-0.14-0.55-0.76-0.47-1.421.89